scholarly journals In-silico Structure Modeling and Docking Studies Using Dipeptidyl Peptidase 4 (DPP4) Inhibitors against Diabetes Type-2

2016 ◽  
Vol 4 (4) ◽  
pp. 73-84
Author(s):  
Rajneesh Prajapat ◽  
Ijen Bhattacharya
Keyword(s):  
In Silico ◽  
Diabetes Type 2 ◽  
Dipeptidyl Peptidase ◽  
Docking Studies ◽  
Diabetes Type ◽  
Structure Modeling ◽  
Dipeptidyl Peptidase 4 ◽  
Dpp4 Inhibitors

scholarly journals Molecular Docking Studies of Phenolic Compounds from Syzygium cumini with Multiple Targets of Type 2 Diabetes

2018 ◽  
Vol 6 (2) ◽  
pp. 125-133
Author(s):  
Ajmer Singh Grewal ◽  
Neelam Sharma ◽  
Sukhbir Singh ◽  
Sandeep Arora
Keyword(s):  
Type 2 Diabetes ◽  
Phenolic Compounds ◽  
Side Effects ◽  
In Silico ◽  
Glycogen Synthase ◽  
Dipeptidyl Peptidase ◽  
Docking Studies ◽  
Multiple Targets ◽  
Dipeptidyl Peptidase 4

Treatment of type 2 diabetes without any side effects is still a challenge to the medical system. This leads to increasing demand for natural products with antidiabetic activity with fewer side effects. Syzygium cumini is a traditional herbal medicinal plant and is reported to possess a variety of pharmacological actions. It contains various types of chemical constituents including terpenoids, tannins, anthocyanins, flavonoids and other phenolic compounds. Some flavonoids and other phenolic compounds from S. cumini were reported in literature to have type 2 antidiabetic potential. The main objective of the current investigation was in silico screening of some phenolic compounds from S. cumini against multiple targets associated with type 2 diabetes to explore the mechanism of antidiabetic action and prediction of binding mode using molecular docking studies. In silico docking studies were performed for the selected molecules in the binding site of multiple targets associated with type 2 diabetes (α-glucosidas , dipeptidyl peptidase 4, glycogen synthase kinase 3, glucokinase and glucagon receptor). Amongst the compounds tested in silico, rutin showed appreciable binding with multiple targets of type 2 diabetes including α-glucosidase, dipeptidyl peptidase 4, glycogen synthase kinase 3, and glucagon receptor. Catechin was found to inhibit both α-glucosidase, and dipeptidyl peptidase 4. This information can be utilized for the design and development of potent multi-functional candidate drugs with minimal side effects for type 2 diabetes therapeuticsa.

scholarly journals Trust and VERIFY: the role of combined treatment with metformin and dipeptidyl peptidase-4 inhibitors in new-onset diabetes type 2

2020 ◽  
Vol 4 (6) ◽  
pp. 334-339
Author(s):  
T.Yu. Demidova ◽  
◽  
A.A. Kozhevnikov ◽  
Keyword(s):  
Combined Treatment ◽  
Diabetes Type 2 ◽  
Dipeptidyl Peptidase ◽  
Diabetes Type ◽  
Glucose Lowering ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucose Lowering Therapy

Diabetes is a progressive disease that manifests itself in hyperglycemia and is associated with macro- and microvascular complications. Stepwise approach to glucose-lowering therapy is now often questioned for two main reasons. First, the decision on intensifying the treatment requires the decompensation of carbohydrate metabolism. Second, this conception does not always meet the criteria of pathophysiological treatment, in particular, in patients who are newly diagnosed with diabetes type 2 and recommended with metformin monotherapy. The combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors is a well-known strategy that effectively controls blood glucose level and preserves beta cell functions. VERIFY study has demonstrated that after a 5-year follow-up, median time to type 2 diabetes decompensation is 36.1 months in metformin group and 61.9 months in early combined treatment group (metformin plus vildagliptin) (p<0.0001). These findings can account for paradigm shift in treatment prescription for newly diagnosed type 2 diabetes in patients with HbA1c less than 1,0% of the target level.KEYWORDS: diabetes, glucose-lowering therapy, control of glycemia, combined treatment.FOR CITATION: Demidova T.Yu., Kozhevnikov A.A. Trust and VERIFY: the role of combined treatment with metformin and dipeptidyl peptidase-4 inhibitors in new-onset diabetes type 2. Russian Medical Inquiry. 2020;4(6):334–339. DOI: 10.32364/2587-6821-2020-4-6-334-339.

scholarly journals Drug-induced diabetes type 2: In silico study involving class B GPCRs

PLoS ONE ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. e0208892 ◽  
Author(s):  
Dorota Latek ◽  
Ewelina Rutkowska ◽  
Szymon Niewieczerzal ◽  
Judyta Cielecka-Piontek
Keyword(s):  
In Silico ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Drug Induced ◽  
In Silico Study ◽  
Class B

In Silico Analysis of New Potent Anti-hyperglycemic Molecule for Diabetes Type 2 Management

2019 ◽  
Vol 26 (2) ◽  
pp. 1031-1042
Author(s):  
Kritika Singh ◽  
Praveen Kumar Tripathi ◽  
Vinay Kumar Singh ◽  
Ashok Kumar Patel ◽  
O. N. Srivastava ◽  
...  
Keyword(s):  
In Silico ◽  
In Silico Analysis ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Silico Analysis

Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes

2010 ◽  
Vol 20 (15) ◽  
pp. 4395-4398 ◽  
Author(s):  
Robert P. Brigance ◽  
Wei Meng ◽  
Aberra Fura ◽  
Thomas Harrity ◽  
Aiying Wang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dpp4 Inhibitors

scholarly journals Oxytocin May be Superior to Gliptins as a Potential Treatment for Diabetic COVID-19 Patients

2021 ◽  
Vol 2 ◽  
pp. 106-107
Author(s):  
Phuoc-Tan Diep
Keyword(s):  
Type 2 Diabetes ◽  
Full Text ◽  
Dipeptidyl Peptidase ◽  
Potential Treatment ◽  
Dipeptidyl Peptidase 4 ◽  
Dpp4 Inhibitors ◽  
Dpp4 Inhibitor ◽  
Increased Risk ◽  
Immunomodulatory Properties

Diabetes is a comorbidity associated with an increased risk of severe COVID-19. Gliptins are anti-diabetic drugs that inhibit dipeptidyl peptidase-4 (DPP4) and they have been proposed as a possible treatment for COVID-19 patients with and without diabetes due to their immunomodulatory properties. Oxytocin has also been proposed as a treatment for COVID-19 due to its immunomodulatory properties as well as other mechanisms. In addition, oxytocin has been identified as a natural DPP4 inhibitor. Therefore, oxytocin not only has the properties associated with DPP4 inhibition but it has numerous additional beneficial properties. It is proposed that oxytocin may be superior to DPP4 inhibitors for COVID-19 patients especially for patients with type 2 diabetes. Doi: 10.28991/SciMedJ-2020-02-SI-10 Full Text: PDF

Sign in / Sign up

Export Citation Format

Share Document